Neurosteroids in human pituitary adenomas

Esra Hatipoglu; Ebubekir Akpinar; Buruc Erkan; Selahattin Yalcinkaya; Şeyma Aksoy; Sebnem Burhan; Omur Gunaldı; Osman Tanriverdi; Mutlu Niyazoğlu

doi:10.1530/endoabs.99.EP1028

EP1028

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP1028 | DOI: 10.1530/endoabs.99.EP1028

ECE2024 Eposter Presentations Pituitary and Neuroendocrinology (214 abstracts)

Neurosteroids in human pituitary adenomas

Esra Hatipoglu ¹ , Ebubekir Akpinar ² , Buruç Erkan ² , Selahattin Yalcinkaya ³ , Şeyma Aksoy ¹ , Sebnem Burhan ¹ , Omur Gunaldı ² , Osman Tanriverdi ² & Mutlu Niyazoğlu ¹

Err

Author affiliations

¹University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Division of Endocrinology, Department of Internal Medicine, Istanbul, Turkey; ²University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Neurosurgery, Istanbul, Turkey; ³Forensic Medicine Specialist 8 th Specialization Committee, the Council of Forensic Medicine of Turkey, Istanbul, Turkey

Neurosteroids refer to hormones with a steroid structure and, their synthesis pathways are identical to those of traditional steroids. However, neurosteroids are generated denovo in the central and peripheral nervous systems and utilize cell surface receptors. Few animal studies indicated synthesis of NS in pituitary. Presence of neurosteroids in human pituitary adenomas(PAs) has yet to be assessed. This is preliminary data of an ongoing study. Seventyseven specimens from human PAs were included. Blood samples were obtained preoperatively. Samples were analyzed by using mass spectrometry. Table 1 compares tissue availability and levels of NS between subgroups of cases with PAs.Tissue levels of DHEA,DHEAS,17-Hydroxyprogesterone and cortisol were correlated with their blood levels (r=+0.3, P=0.04; r=+0.6, P<0.001; r=+0.7, P=0.005 and r=+0.4, P<0.001,respectively). In conclusion PAs harbor neurosteroids.The tissue type can have an impact on both diversity and levels of neurosteroids. Further investigations can determine whether the pituitary gland is the origin or recipient.

Table 1.
	NFA n=43)	Somato-tropinoma (n=20)	Cortico-tropinoma (n=9)	Prolactinoma (n=5)	p
PREG
Availability*	36 (86%)	6 (3%)	4 (44%)	1 (20%)	0.04
Level**	104.6[43.7-202]	0.3[0-1.8]	0.7[0-2.8]	21.3	0.05
7OHPREG
Availability*	3 (33%)	16 (80%)	32 (74%)	3 (60%)	0.06
Level**	47.1[18.5-106.3]	36.6 [10.1-25.8]	45.4[32.9-45.4]	41.4[34.6-184.5]	0.9
DHEA
Availability*	36 (84%)	16 (80%)	6 (67%)	4 (80%)	0.7
Level**	8.1[4.8-20.9]	11.7[7.8-20]	18.1[11.5-50.3]	64.1[30.7-444.2]	0.04
DHEAS
Availability*	43 (100%)	20 (100%)	9 (100%)	5 (100%)	-
Level**	16.4[7.2-46.2]	30.4 [15.6-42.9]	31[16.6-106.7]	55.3[23.5-202.9]	0.06
AE
Availability*	16 (37%)	10 (50%)	3 (33%)	1 (20%)	0.6
Level**	0.5[0.3-1.5]	0.8[0.4-1.2]	1.7[0.3-3.7]	0.6	0.6
T
Availability*	27 (63%)	10 (50%)	2 (22%)	1 (20%)	0.06
Level**	0.7[0.5-1.5]	0.8[0.5-0.9]	2.5 [2-2.9]	0.9	0.3
DHT
Availability*	2 (5%)	1 (5%)	1 (11%)		0.8
Level**	38.1	99.7	3.3		0.4
Androsterone
Availability*	24 (56%)	11 (55%)	4 (44%)	5 (100%)	0.2
Level**	10.5[1.8-39.2]	17.3[3.7-31.8]	12.4[2.6-390.7]	19.1[3.7-143.7]	0.9
PRG
Availability*	5 (2%)	1 (5%)	2 (22%)		0.5
Level**	0.9	0.9	2.9		0.9
ALLO
Availability*	1 (1%)
Level**	148.5
DOC
Availability*	13 (30%)	7 (35%)	2 (22%)		0.5
Level**	0.4	0.7	1.9		0.07
Corticosterone
Availability*	9 (21%)	6 (3%)	1 (11%)	1 (20%)	0.7
Level**	1.3[0.4-4]	0.9[0.6-3.8]	9.7[1.2-2.7]	0.8	0.4
Aldosterone
Availability*	2 (5%)
Level**	0.7[0.39-]
17OHPRG
Availability*	7 (16%)	4 (20%)	2 (22%)	2 (40%)	0.6
Level**	0.9	0.7	1.7	2.9	0.8
11 Deoxycortisol
Availability*	43 (100%)	20 (100%)	9 (100%)	5 (100%)
Level**	1	1.7	3.1	6	<0.001
Cortisol
Availability*	43 (100%)	19 (95%)	8 (89%)	4 (80%)	0.09
Level**	4.7[1.9-7.9]	6.1[2.9-12.8]	12.1 [7.7-30.1]	10 [2.5-45]	0.04
*	n	(%),**	ng/g